Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and ...

Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...

The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025 ...

The research, led by the ALS Association in collaboration with several leading ALS clinicians, examined Medicare claims made from 2011 to 2021 and found that the average time for ...

Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES - (NewMediaWire) - - Clene (NASDAQ: CLNN) ...

It can take twice as long for people to receive an ALS diagnosis if they are seen in a general neurology clinic compared to a specialist clinic, ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...